#Imbruvica

The newer targeted therapy zanubrutinib works better and has fewer side effects than the older ibrutinib.

Research at #ASH22 calls into question longstanding assumptions and charts a path for gentler therapies.

For those with undetectable minimal residual disease, treatment discontinuation was as effective as staying on Imbruvica.

Studies suggest BTK inhibitors and hormone therapy might lessen disease severity and speed recovery.

Imbruvica plus Rituxan delayed disease progression when compared with a triple chemotherapy regimen.

Imbruvica, Calquence and Venclexta demonstrate good results in combination regimens.

Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.

Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.

Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.

Customized cell therapy plus Imbruvica leads to high response rate.

Revlimid improves outcomes for chronic lymphocytic leukemia patients, but better drugs are now available.